Best Ideas 2019 features all the nominated entries submitted under ‘Submit your Idea’ category. All the entries consist of innovative solutions or propositions for an enterprise that champions the Sustainable Development Goals. They can be on the conceptual, planning, or start-up stage.
Genius in Healthcare: Non-invasive, point of care sensor for early detection of kidney damage
Explain your idea in details:
Kidney diseases are now recognized as a public health epidemic affecting over 850 million people globally. Chronic kidney disease [CKD] is a silent, asymptomatic disease where most of the patients are unaware of this condition persisting in their body. It is usually found at the later stage when the kidney is irreversibly damaged. Retrospectively, we have come up with an objective to cease the progression of kidney damage towards the irreversible stage and to reduce the burden of dialysis by detecting the damage at the earliest possible juncture. Our product, RENASENS, will tackle down the major current bottlenecks in blood-based diagnostics with imperative cutting-edge microfluidic sensing technology. Currently, there are certain diagnostic techniques in practice which is carried out via the measurement of serum urea nitrogen, creatinine, albumin, and estimated glomerular filtration, However, these tactics are invasive and time-consuming during which, half millions of nephrons may be damaged. This can be eased by RENASENS, a novel low-cost, rapid, user-friendly, point of care and a non-invasive sensor which gives results within 5 min, compared to 2 hrs at the lab thereby eliminating frequent visits of patients to the pathology lab. We have targeted a potent early kidney damage indicator, biomarker in urine and concentration of biomarker is quantified for correlation to the affliction of the kidney which allows accurate and sensitive detection of kidney damage at the earliest stage. Not limiting to this area our highly scalable sensor can be used as a diagnostic tool in clinical trials during drug screening also used as a routine diagnostic tool for patients who are taking several medications which are nephrotoxic in long term. Conclusively, this biosensor lays emphasis over the on-site test allowing patients high mobility and flexibility, reducing the risk of severe progression of CKD towards end-stage or the economic burden of dialysis.
Expected impact of your idea on sustainable development
This idea aims at making a real difference in the clinical management and diagnosis of kidney disease, by reinventing existing paradigms of preventions. This partly results from a suboptimal diagnostic tool and lack of early detection. Our ultimate goal is to stop the progression of kidney damage to irreversible stage and reduce the burden of dialysis. This will hugely impact on sustainable goals in various way. Firstly, by detecting kidney damage at an earliest possible stage, patients outcomes could be improved by identifying high-risk groups, thereby permitting targeted therapy to be implemented to reduce the incidence of adverse effects such as progression to end-stage renal disease (ESRD), cardiovascular events and mortality. Secondly, drug safety and appropriate monitoring of toxic effects are also enhanced with early identification of renal impairment. In addition, potential savings to the health-care system and individuals may be made. Finally, the increased costs associated with the treatment of the CKD population are largely a result of the high rates of comorbidity-driven admission and extended hospital stays that are required as CKD progresses. Thus, the costs incurred during the early stages of CKD increase markedly with progression to ESRD and remains elevated. For instance, if we take an Indian cost scenario, in India every year 3.4 crore patients require dialysis and the approximately average cost per dialysis session is 4000. If 5 % of this population can be diagnosed at an early stage and eliminated from dialysis, so we can potentially save 6.8 Billion in healthcare cost. Renal transplant cost of 2.25 Billion can be avoided as every year 7500 renal transplants are required. By implementing our idea, we can reduce most of this financial catastrophe as well as it can ensure healthy lives and promote the well-being of people of all ages.
Plans for implementation and sustainability
The introduction of service innovation is complex and dynamic. To make it work eminently it should not exist in isolation but should require an entire package of interventions for a significant change in the way health care services function, Hence to create a close marketing loop our team believes in [Business to business to consumer] business model approach and collaborating with major medical centers, pathology labs and pharmacy stores, The revenue is expected to be driven from these different sources, who in turn will sell our product to patients and will provide an effective opportunity to commercialize it. Our team will get a certain part of the money that our partners charge to patients. Currently, we are at the prototype testing phase for clinical evaluation. In this stage, we will need funding support from various ventures where we will collaborate with well-known institutes for clinical evaluations and endorsements from doctors who will be our key opinion leader (KOL) are substantial in regulating patients emotions and their adherence to the prescribed treatment and other medical personnel. To keep the process functional, continued evaluation of RENASENS would be fundamental for sustainable implementation and scale-up, Constant feedback on the quality of the device will be the key to improve the strategies. In the end, leadership and management considering all the discussed points will maintain our compelling and clear vision for the sustainability of our product.
Team CHIMERA, involves the members of multidisciplinary science and innovation focusing on innovation. The motive of this team is to create affordable, commercialize solutions for several unmet medical problems. By using our strengths in research and technology to develop solutions would transcend beyond publications/patents and reach to their real users [patients] for their greater deeds. Our team is interested in translational research, fabrication and surface modification of certain specific materials and its application in biosensors, rapid diagnostics, and microfluidic-based devices. With an aim is to use technology to make a difference in the lives of the people and community around us, CHIMERA is led by two people Mit Patel M.S. [Pharma] in Medical devices and Aishwarya Rajaram Hiray M.Sc. [Intr.] Biotechnology. During the Masters period, our team members won several awards such as the Biotechnology Entrepreneurship Student Team [ABLE - BEST] 2018 with a cash prize of 0.3 million. This had a huge contribution to strengthening our business tactics and management skills. Mit Patel, a 22-year-old Indian youth, is someone who demonstrates an unwavering resolve to do whatever must be done to produce the best long-term results, no matter how difficult. He is trained in domain of biosensors, microfluidics and tissue engineering. The foundation of these courses led him to win Shushruta innovation award 2018 Aishwarya Hiray, a 24-year-old Indian youth, committed to hard work is trained in the domain of Genetic engineering, Molecular Biology. Her need to comprehend the reason behind things and ability to understand and explain a concept, she was given an opportunity to be part of a team to organize Indias first International Conference on Nutrigenomics and Nutrigenetics [ICONN]. She has bragged an award in making a working model of Heart Beat Monitor in Biofest 2014 at her institute.